Parallax Volatility Advisers, L.P. Seres Therapeutics, Inc. Transaction History

Parallax Volatility Advisers, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.93 - $2.15 $28,231 - $65,265	-30,356 Reduced 41.29%	43,163 $60,000
Q3 2023 Nov 14, 2023	SELL	$2.33 - $5.07 $143,020 - $311,206	-61,382 Reduced 45.5%	73,519 $174,000
Q2 2023 Aug 14, 2023	BUY	$4.67 - $6.55 $629,987 - $883,601	134,901 New	134,901 $646,000
Q3 2022 Nov 14, 2022	SELL	$3.5 - $7.2 $189,049 - $388,900	-54,014 Reduced 54.01%	45,986 $295,000
Q2 2022 Aug 15, 2022	BUY	$2.7 - $7.62 $270,000 - $762,000	100,000 New	100,000 $343,000

Q1 2018 May 15, 2018	SELL	$7.34 - $11.16 $22,812 - $34,685	-3,108 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$9.15 - $12.64 $28,438 - $39,285	3,108	3,108 $32,000

100

62.7M

36.9K

476K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.